*Sponsored
Market Crux Announces Coverage On (CTXR) Starting Tomorrow
—Thursday, October 16, 2025
Here's Why…
Recent Momentum: (CTXR) Made An Approximate 36% Move
In Just The Last Few Weeks.
Analyst Coverage: Target Suggests Over 350% Upside Potential For (CTXR)
Limited Float: (CTXR) Has Less Than 17M Shares Listed In Its Float
Which Could Lead To The Potential For Big Moves If Demand Begins To Shift.
Take A Look At (CTXR) Before Tomorrow Morning…
October 15, 2025
Tomorrow's Watchlist | See Why (Nasdaq: CTXR) Is Flying Under the Radar Dear Reader, Momentum in biotech has been quiet lately — but one name is starting to break that pattern. Tomorrow, Thursday, October 16, 2025, Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) moves to the top of our morning watchlist. Still under $2, (CTXR) has been quietly advancing on several critical fronts — from an FDA-cleared therapy preparing for commercial rollout to late-stage data in an area with no approved solutions, and a third program closing in on pivotal development. This combination of late-stage assets, regulatory wins, and commercial readiness positions (CTXR) for what could be a defining moment in 2025. With fewer than 17M shares listed in its float, there's the potential for big moves if demand starts to shift. And we've already seen early signs of that. Over the last few weeks, (CTXR) has made an approximate 36% move, from $1.11 on September 29 to $1.52 on October 7. Now, (CTXR) is trending above several key technical levels, including its 5, 20, 50, and 100-Day moving averages. Analyst Coverage Points to 350% Upside Potential for (CTXR)
(CTXR) has started crossing over from quiet chatter to serious coverage. As of October 15, Jason Kolbert of D. Boral Capital has a $6 target on (CTXR), which suggests 350% upside potential from this week's $1.32 range, as reported by Benzinga and TipRanks. 
When you line up against (CTXR)'s recent approximate 36% move, the message is hard to miss: analysts see more room for this story to run. And the timing couldn't be better. In its Q3 2025 update, (CTXR) confirmed that it's gearing up for its first U.S. commercial launch in Q4 2025. With $12.5M raised during the quarter, another $9M raised in July, and $6.1M in cash as of June 30, management says the company is now "operationally positioned" to deliver. That combination — analyst targets calling for triple-digit upside, strong financing momentum, and the transition to a fully integrated commercial organization — is why Citius is starting to look less like a development-stage story and more like a breakout-ready name. Inside (CTXR)'s Expanding Pipeline of Late-Stage Programs (CTXR) has three major programs moving forward, each designed to address areas where treatment options are limited or don't exist at all. The most advanced is LYMPHIR™, a therapy already approved by the FDA in 2024 for a rare type of skin-related cancer called cutaneous T-cell lymphoma (CTCL). 
This was the first new treatment approved for CTCL in years, giving hope to patients who previously had few options. Citius has put nearly $90M into this program, and it's now preparing for a full U.S. launch later this year (Q4 2025) through its subsidiary, Citius Oncology. …Backed by a national distribution deal with Cardinal Health, LYMPHIR is expected to target a market worth more than $400M annually in the U.S. And ahead of the rollout, Citius Oncology recently deployed a proprietary AI platform designed to enhance the precision and efficiency of its commercial operations. The system uses real-world data and machine learning to help identify physicians whose patients may benefit from LYMPHIR, strengthening sales targeting and supporting more informed engagement. According to CEO Leonard Mazur, this AI integration marks another step toward building a smarter, data-driven launch strategy that aligns clinical expertise with patient access. On top of that, researchers are also testing LYMPHIR in combination with other cancer therapies like KEYTRUDA® and in next-generation treatments like CAR-T, opening the door to even bigger possibilities in the future. The second program, Mino-Lok®, is designed to treat serious infections that occur when catheters (tubes placed into veins) get contaminated. 
Right now, when that happens, doctors often have to remove and replace the catheter — a risky and expensive procedure. Mino-Lok has already completed a large late-stage study showing that it can save infected catheters while keeping patients safe, and there are currently no approved treatments that can do this. With the potential to serve a market estimated at over $1B in the U.S. alone, Mino-Lok could fill a huge gap in care. The third program, Halo-Lido, is focused on hemorrhoids — a very common condition that affects more than 10M people in the U.S. Despite how widespread it is, there are currently no FDA-approved prescription products for it. In a mid-stage study, Halo-Lido showed promising results in reducing symptoms and improving patient comfort. (CTXR) is now working with the FDA on the next steps to bring this program closer to approval. Taken together, these three programs represent a diversified approach: one product already FDA-approved and preparing for launch, another that has shown strong results in late-stage testing, and a third moving toward pivotal trials. For those who want to dive deeper into the science and see the full clinical details, (CTXR) provides a detailed corporate presentation that outlines each program's progress and future milestones. This kind of pipeline breadth is rare for a company still at these levels — and it's exactly why eyes could start to shift in this direction. 7 Things to Know About (CTXR) Before Tomorrow's Open
—Thursday, October 16, 2025
1. Recent Momentum: Over the past few weeks, (CTXR) has made an approximate 36% move, from $1.11 on September 29 to $1.52 on October 7, showing clear momentum potential. 2. Analyst Target: Coverage on (CTXR) from D. Boral Capital includes a target that suggests over 350% upside potential. 3. Small Float: With fewer than 17M shares in the float, (CTXR) could see the potential for big moves if attention starts to shift. 4. Under The Radar: still sitting at less than $2, (CTXR) appears to be flying under the radar—and for many readers, this could still be a discovery story in motion. 5. Late-Stage Strength: In late-stage testing, (CTXR)'s Mino-Lok program outperformed in treating dangerous bloodstream infections. 6. AI Integration: through its subsidiary Citius Oncology, (CTXR) recently deployed an AI platform to enhance precision targeting and streamline the LYMPHIR launch strategy. 7. Ready for Rollout: An FDA-cleared therapy from (CTXR) is slated for a nationwide rollout in Q4 2025. Each of these factors is compelling on its own, but together they form a setup that's hard to overlook. Momentum, potential catalysts, and timing are converging in a way that rarely comes along in this space. Take A Look At (CTXR) Before Tomorrow Morning…
With (CTXR) still trending below $2, this name remains largely under the radar even as it advances multiple late-stage programs and prepares for a nationwide commercial rollout. Over the past few weeks, momentum has started to build —(CTXR) made an approximate 36% move onto our radar. With fewer than 17M shares in the float, any shift in attention could carry extra weight as the company enters a defining stretch marked by pivotal data, expanding analyst coverage, and a fast-approaching FDA-cleared launch. We'll be watching (CTXR) closely as Thursday's session approaches. Give it a quick look tonight so you're ready before the bell. I'll have the early update waiting in your inbox tomorrow morning. Have a good night. Sincerely, Gary Silver
Managing Editor, Market Crux
| 
